BAX and acute myeloid leukemia: The small molecule BAX agonists SMBA1, SMBA2, and SMBA3 selectively bind to BAX and inhibit S184 phosphorylation, thereby promoting BAX insertion into mitochondrial membranes and the formation of BAX oligomers, and inducing conformational changes in BAX, ultimately leading to cytochrome c release and apoptosis.1176 Other BAX-activating compounds, such as BAM-7 and BTSA1, also have antitumor activity in glioblastoma and AML cells.463,1177 Meanwhile, some other preclinical inhibitors are also under investigation.463